Asymchem plans additional investment in Dunhua facility
pharmafile | February 21, 2012 | News story | Manufacturing and Production | Asymchem, China, Dunhua, manufacturing
China’s Asymchem Laboratories says it plans to invest another $12 million in its recently-opened manufacturing facility in Dunhua, Jilin province, in order to increase downstream capacity in the face of ‘exceptional customer demand’.
Asymchem started operations at the commercial-scale manufacturing facility towards the end of last year, saying at the time that it had already invested $20 million in the plant between 2009 and 2011.
The Dunhua plant makes raw materials, including chemicals and intermediates used in pharmaceutical manufacturing, and was built to meet demand for projects greater than five metric tonnes, according to the company.
The new facility can accommodate high-volume processes as a standalone service, as well as back-end integration for starting materials or intermediates that will then be further processed in Asymchem’s Tianjin and Fuxin facilities, it said.
The new facility will free up capacity at other Asymchem’s sites in China, allowing its manufacturing resources to be used in a more efficient manner.
“We had exhausted the resources at our other locations,” said Hao Hong, Asymchem’s chief executive.
Having Dunhua operational will support existing and new manufacturing contracts, and will help the company expand in the global custom development and manufacturing markets, he added.
The first phase of the plant’s construction involved the installation of 5,000 to 20,000-litre production vessels, with a second phase due to complete in July. A third phase of construction to add the capacity to make active pharmaceutical ingredients (APIs) is due to complete in October. By the end of the year capacity will have tripled.
“Asymchem will continually look towards investing in world-class facilities and new technology developments as a strategy for success,” said Hong.
“We believe that this is the primary path forward in maintaining competitiveness as the global market evens out across the international and domestic Chinese intermediates and API markets.”
Phil Taylor
Related Content
CARBOGEN AMCIS manufacturing license advances services in China
Swiss pharma manufacturing company, CARBOGEN AMCIS, has announced that its facility in Shanghai, China, has …
Meribel Pharma Solutions launches to take pharma services to new heights
Meribel Pharma Solutions, a new mid-sized contract development and manufacturing organisation (CDMO), has officially launched …
Bend Bioscience adds commercial spray drying facility to Georgia site
Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry …
